Addressing the Disparity: Treating Childhood Cancer in Low and Middle-Income Countries

By Staff Writer

December 13, 2023

The Stark Reality of Childhood Cancer Treatment in LMICs

Every year, the World Health Organisation (WHO) reports an estimated 400,000 children and adolescents aged 0-19 develop cancer. The most common types are leukaemias, brain cancers, lymphomas, and solid tumours, such as neuroblastoma and Wilms tumours. High-income countries (HICs), which house only 20% of the world’s children with cancer, boast cure rates exceeding 80%. In stark contrast, Childhood Cancer Treatment in LMICs only manage a 30% cure rate.

The Challenges of Healthcare in LMICs

The economies of most LMICs are at an early stage of development, marked by poverty, health-care worker shortages, weak health systems, low education levels, and limited access to modern technology and healthcare facilities. Paediatric oncology, the specialised field dealing with cancers in children and adolescents, demands a high level of expertise and resources. Unfortunately, these are often lacking in LMICs, exacerbating the problem of childhood cancer.

The Essential Components of Effective Childhood Cancer Treatment

Effective treatment of childhood cancer requires a robust system with specialised diagnostic and therapeutic capabilities. Key elements include trained paediatric oncologists, surgeons, pathologists, radiation oncologists, radiologists, pharmacists, and nurses. Reliable supplies of chemotherapeutic agents, supportive care medications, and blood products are crucial. Diagnostic imaging capabilities and basic laboratory services are also vital. However, even with these in place, treatment abandonment remains a significant cause of treatment failure in many LMICs.

The Importance of National Cancer Plans (NCPs) in LMICs

Most LMICs lack policies to ensure good paediatric oncology care and do not have a National Cancer Plan (NCP). An NCP is a public health programme aimed at increasing diagnosis, reducing the number of deaths, and improving the quality of life of cancer patients. It promotes the development of management guidelines, emphasises early referral pathways, lowers morbidity and mortality, and improves the quality of life of cancer patients, regardless of their birthplace.

Education and Training Initiatives in LMICs

Education and public awareness are crucial components in the fight against childhood cancer. For instance, the CHOC Childhood Cancer Foundation has been collaborating with the Department of Health and Traditional Healers Organisations since 2011 to educate health professionals, healthcare workers, and communities about childhood cancer. This initiative aims to bust myths, reduce stigma, and improve early diagnosis and treatment. Furthermore, CHOC has recently trained its employees and volunteers on how to become effective facilitators and advocates in communities. To date, they have trained close to 30,000 trainees in seven of the nine provinces of South Africa, demonstrating a significant stride towards improving childhood cancer outcomes in LMICs.

Reference url

Recent Posts

cervical cancer prevention
    

Cervical Cancer Prevention Strategies: Insights from South African

🌍 Did you know South African women living with HIV face a significantly higher risk of cervical cancer?

Our latest article looks into the perspectives of women and their partners regarding innovative cervical cancer prevention strategies, including the acceptability of the intravaginal 5-fluorouracil (5FU) treatment. It highlights the critical role of education and counseling in improving screening uptake and treatment adherence.

Explore how we can enhance cervical health for vulnerable populations!

#SyenzaNews #globalhealth #oncology #HealthcareInnovation

MPA meningioma risk
       

MPA Meningioma Risk: Key Insights and Implications

⚠️ *Are you aware of the new safety warnings surrounding medroxyprogesterone acetate (MPA)?*
The South African Health Products Regulatory Authority (SAHPRA) has clarified crucial information regarding the potential **MPA meningioma risk** associated with prolonged use of this synthetic hormone. While the absolute risk remains low, the implications for patients and healthcare providers are significant.

Dive into the article to understand the updated guidelines and what they mean for clinical practice.

#SyenzaNews #healthcare #oncology #HealthEconomics

MENA generics biologics growth
        

MENA Generics Biologics Healthcare Innovation

💡 *What does the future hold for healthcare in the MENA region?*
The rise of generics and biologics is set to transform healthcare in the Middle East and North Africa, driven by government reforms and an evolving regulatory landscape. Learn how these advancements are making life-saving therapies more accessible and cost-effective for patients across the region.

#SyenzaNews #HealthcareInnovation #pharmaceuticals #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.